Global NGS for Cancer Early Screening Market Research Report 2026(Status and Outlook)
Early cancer screening (tumor early screening) refers to the use of a fast and simple method to screen out a very small number of high-risk tumor groups from a large number of healthy target populations that have not yet shown symptoms, so as to detect tumors early and reduce the risk of disease, especially cancers with high incidence, high mortality, and long enough development cycles, such as gastric cancer, lung cancer, colorectal cancer, etc. People who do not have clear high-risk factors for tumors are more suitable for pan-cancer early screening (although pan-cancer early screening can detect multiple tumors at the same time, it may not be able to determine which type of tumor it is), while those with a clear family history of tumors and high-risk groups choose single cancer early screening. Early screening testing service providers currently have two commercial models: IVD and LDT. IVD sells reagent products and needs to be approved by FDA/NMPA before they can be put on the market; while LDT sells services and provides testing services to hospitals, physical examination companies and other institutions. It mainly provides testing needs with strong specificity and difficult to standardize, but the products have not yet been approved by regulatory authorities such as the FDA. Compared with the IVD model, the LDT model can quickly return funds and reduce the time for regulatory approval. Therefore, most early cancer screening companies will choose to provide services through the LDT model first. In this process, they will replenish R&D funds and collect clinical data, and then switch to the IVD model to obtain product registration certificates to gain market share. NGS (next generation sequencing technology) is the "engine" of detection, which can efficiently and accurately analyze the genomic and epigenomic changes (such as methylation patterns and mutation characteristics) of free DNA (cfDNA) or circulating tumor DNA (ctDNA) in the blood. NGS itself does not directly "diagnose cancer", but distinguishes cancer signals from background noise by detecting specific biomarkers (such as methylation, mutation) and combining machine learning algorithms.
The global NGS for Cancer Early Screening market size was estimated at USD 638.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 22.10% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global NGS for Cancer Early Screening market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global NGS for Cancer Early Screening market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the NGS for Cancer Early Screening market.
Global NGS for Cancer Early Screening Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Guardant Health
Exact Sciences
Freenome
Epiginomics AG
Bio-techne
ThriveEarlier Detection
GRAIL, Inc.
CellMax life
Berry Genomics
Singlera Genomics
Geneseeq
BGI Genomics
Burning Rock Biotech Limited
New Horizon Health Limited
Yeasen Bio
Hangzhou Aoru Biotech
Amoy Diagnostics Co., Ltd.
Genetron Health
AnchorDx
Market Segmentation (by Type)
ctDNA Gene Mutation Detection
cfDNA Methylation Sequencing
Market Segmentation (by Application)
Medical Institutions
Physical Examination Centers
Geographic Segmentation
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the NGS for Cancer Early Screening Market
Overview of the regional outlook of the NGS for Cancer Early Screening Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the NGS for Cancer Early Screening Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of NGS for Cancer Early Screening, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global NGS for Cancer Early Screening market size was estimated at USD 638.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 22.10% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global NGS for Cancer Early Screening market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global NGS for Cancer Early Screening market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the NGS for Cancer Early Screening market.
Global NGS for Cancer Early Screening Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Guardant Health
Exact Sciences
Freenome
Epiginomics AG
Bio-techne
ThriveEarlier Detection
GRAIL, Inc.
CellMax life
Berry Genomics
Singlera Genomics
Geneseeq
BGI Genomics
Burning Rock Biotech Limited
New Horizon Health Limited
Yeasen Bio
Hangzhou Aoru Biotech
Amoy Diagnostics Co., Ltd.
Genetron Health
AnchorDx
Market Segmentation (by Type)
ctDNA Gene Mutation Detection
cfDNA Methylation Sequencing
Market Segmentation (by Application)
Medical Institutions
Physical Examination Centers
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the NGS for Cancer Early Screening Market
Overview of the regional outlook of the NGS for Cancer Early Screening Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the NGS for Cancer Early Screening Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of NGS for Cancer Early Screening, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of NGS for Cancer Early Screening
1.2 Key Market Segments
1.2.1 NGS for Cancer Early Screening Segment by Type
1.2.2 NGS for Cancer Early Screening Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NGS FOR CANCER EARLY SCREENING MARKET OVERVIEW
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NGS FOR CANCER EARLY SCREENING MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global NGS for Cancer Early Screening Product Life Cycle
3.3 Global NGS for Cancer Early Screening Revenue Market Share by Company (2020-2025)
3.4 NGS for Cancer Early Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.5 Headquarters, Areas Served, and Product Types of Major Players
3.6 NGS for Cancer Early Screening Market Competitive Situation and Trends
3.6.1 NGS for Cancer Early Screening Market Concentration Rate
3.6.2 Global 5 and 10 Largest NGS for Cancer Early Screening Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NGS FOR CANCER EARLY SCREENING VALUE CHAIN ANALYSIS
4.1 NGS for Cancer Early Screening Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NGS FOR CANCER EARLY SCREENING MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global NGS for Cancer Early Screening Market Porter's Five Forces Analysis
6 NGS FOR CANCER EARLY SCREENING MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global NGS for Cancer Early Screening Market by Type (2020-2025)
6.3 Global NGS for Cancer Early Screening Market Size Growth Rate by Type (2021-2025)
7 NGS FOR CANCER EARLY SCREENING MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global NGS for Cancer Early Screening Market Size (M USD) by Application (2020-2025)
7.3 Global NGS for Cancer Early Screening Market Size Growth Rate by Application (2021-2025)
8 NGS FOR CANCER EARLY SCREENING MARKET SEGMENTATION BY REGION
8.1 Global NGS for Cancer Early Screening Market Size by Region
8.1.1 Global NGS for Cancer Early Screening Market Size by Region
8.1.2 Global NGS for Cancer Early Screening Market Size Market Share by Region
8.2 North America
8.2.1 North America NGS for Cancer Early Screening Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe NGS for Cancer Early Screening Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Spain
8.4 Asia Pacific
8.4.1 Asia Pacific NGS for Cancer Early Screening Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America NGS for Cancer Early Screening Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa NGS for Cancer Early Screening Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Guardant Health
9.1.1 Guardant Health Basic Information
9.1.2 Guardant Health NGS for Cancer Early Screening Product Overview
9.1.3 Guardant Health NGS for Cancer Early Screening Product Market Performance
9.1.4 Guardant Health SWOT Analysis
9.1.5 Guardant Health Business Overview
9.1.6 Guardant Health Recent Developments
9.2 Exact Sciences
9.2.1 Exact Sciences Basic Information
9.2.2 Exact Sciences NGS for Cancer Early Screening Product Overview
9.2.3 Exact Sciences NGS for Cancer Early Screening Product Market Performance
9.2.4 Exact Sciences SWOT Analysis
9.2.5 Exact Sciences Business Overview
9.2.6 Exact Sciences Recent Developments
9.3 Freenome
9.3.1 Freenome Basic Information
9.3.2 Freenome NGS for Cancer Early Screening Product Overview
9.3.3 Freenome NGS for Cancer Early Screening Product Market Performance
9.3.4 Freenome SWOT Analysis
9.3.5 Freenome Business Overview
9.3.6 Freenome Recent Developments
9.4 Epiginomics AG
9.4.1 Epiginomics AG Basic Information
9.4.2 Epiginomics AG NGS for Cancer Early Screening Product Overview
9.4.3 Epiginomics AG NGS for Cancer Early Screening Product Market Performance
9.4.4 Epiginomics AG Business Overview
9.4.5 Epiginomics AG Recent Developments
9.5 Bio-techne
9.5.1 Bio-techne Basic Information
9.5.2 Bio-techne NGS for Cancer Early Screening Product Overview
9.5.3 Bio-techne NGS for Cancer Early Screening Product Market Performance
9.5.4 Bio-techne Business Overview
9.5.5 Bio-techne Recent Developments
9.6 ThriveEarlier Detection
9.6.1 ThriveEarlier Detection Basic Information
9.6.2 ThriveEarlier Detection NGS for Cancer Early Screening Product Overview
9.6.3 ThriveEarlier Detection NGS for Cancer Early Screening Product Market Performance
9.6.4 ThriveEarlier Detection Business Overview
9.6.5 ThriveEarlier Detection Recent Developments
9.7 GRAIL, Inc.
9.7.1 GRAIL, Inc. Basic Information
9.7.2 GRAIL, Inc. NGS for Cancer Early Screening Product Overview
9.7.3 GRAIL, Inc. NGS for Cancer Early Screening Product Market Performance
9.7.4 GRAIL, Inc. Business Overview
9.7.5 GRAIL, Inc. Recent Developments
9.8 CellMax life
9.8.1 CellMax life Basic Information
9.8.2 CellMax life NGS for Cancer Early Screening Product Overview
9.8.3 CellMax life NGS for Cancer Early Screening Product Market Performance
9.8.4 CellMax life Business Overview
9.8.5 CellMax life Recent Developments
9.9 Berry Genomics
9.9.1 Berry Genomics Basic Information
9.9.2 Berry Genomics NGS for Cancer Early Screening Product Overview
9.9.3 Berry Genomics NGS for Cancer Early Screening Product Market Performance
9.9.4 Berry Genomics Business Overview
9.9.5 Berry Genomics Recent Developments
9.10 Singlera Genomics
9.10.1 Singlera Genomics Basic Information
9.10.2 Singlera Genomics NGS for Cancer Early Screening Product Overview
9.10.3 Singlera Genomics NGS for Cancer Early Screening Product Market Performance
9.10.4 Singlera Genomics Business Overview
9.10.5 Singlera Genomics Recent Developments
9.11 Geneseeq
9.11.1 Geneseeq Basic Information
9.11.2 Geneseeq NGS for Cancer Early Screening Product Overview
9.11.3 Geneseeq NGS for Cancer Early Screening Product Market Performance
9.11.4 Geneseeq Business Overview
9.11.5 Geneseeq Recent Developments
9.12 BGI Genomics
9.12.1 BGI Genomics Basic Information
9.12.2 BGI Genomics NGS for Cancer Early Screening Product Overview
9.12.3 BGI Genomics NGS for Cancer Early Screening Product Market Performance
9.12.4 BGI Genomics Business Overview
9.12.5 BGI Genomics Recent Developments
9.13 Burning Rock Biotech Limited
9.13.1 Burning Rock Biotech Limited Basic Information
9.13.2 Burning Rock Biotech Limited NGS for Cancer Early Screening Product Overview
9.13.3 Burning Rock Biotech Limited NGS for Cancer Early Screening Product Market Performance
9.13.4 Burning Rock Biotech Limited Business Overview
9.13.5 Burning Rock Biotech Limited Recent Developments
9.14 New Horizon Health Limited
9.14.1 New Horizon Health Limited Basic Information
9.14.2 New Horizon Health Limited NGS for Cancer Early Screening Product Overview
9.14.3 New Horizon Health Limited NGS for Cancer Early Screening Product Market Performance
9.14.4 New Horizon Health Limited Business Overview
9.14.5 New Horizon Health Limited Recent Developments
9.15 Yeasen Bio
9.15.1 Yeasen Bio Basic Information
9.15.2 Yeasen Bio NGS for Cancer Early Screening Product Overview
9.15.3 Yeasen Bio NGS for Cancer Early Screening Product Market Performance
9.15.4 Yeasen Bio Business Overview
9.15.5 Yeasen Bio Recent Developments
9.16 Hangzhou Aoru Biotech
9.16.1 Hangzhou Aoru Biotech Basic Information
9.16.2 Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Overview
9.16.3 Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Market Performance
9.16.4 Hangzhou Aoru Biotech Business Overview
9.16.5 Hangzhou Aoru Biotech Recent Developments
9.17 Amoy Diagnostics Co., Ltd.
9.17.1 Amoy Diagnostics Co., Ltd. Basic Information
9.17.2 Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Overview
9.17.3 Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Market Performance
9.17.4 Amoy Diagnostics Co., Ltd. Business Overview
9.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
9.18 Genetron Health
9.18.1 Genetron Health Basic Information
9.18.2 Genetron Health NGS for Cancer Early Screening Product Overview
9.18.3 Genetron Health NGS for Cancer Early Screening Product Market Performance
9.18.4 Genetron Health Business Overview
9.18.5 Genetron Health Recent Developments
9.19 AnchorDx
9.19.1 AnchorDx Basic Information
9.19.2 AnchorDx NGS for Cancer Early Screening Product Overview
9.19.3 AnchorDx NGS for Cancer Early Screening Product Market Performance
9.19.4 AnchorDx Business Overview
9.19.5 AnchorDx Recent Developments
10 NGS FOR CANCER EARLY SCREENING MARKET FORECAST BY REGION
10.1 Global NGS for Cancer Early Screening Market Size Forecast
10.2 Global NGS for Cancer Early Screening Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe NGS for Cancer Early Screening Market Size Forecast by Country
10.2.3 Asia Pacific NGS for Cancer Early Screening Market Size Forecast by Region
10.2.4 South America NGS for Cancer Early Screening Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Sales of NGS for Cancer Early Screening by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
11.1 Global NGS for Cancer Early Screening Market Forecast by Type (2026-2035)
11.1.1 Global NGS for Cancer Early Screening Market Size Forecast by Type (2026-2035)
11.2 Global NGS for Cancer Early Screening Market Forecast by Application (2026-2035)
11.2.1 Global NGS for Cancer Early Screening Market Size (M USD) Forecast by Application (2026-2035)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of NGS for Cancer Early Screening
1.2 Key Market Segments
1.2.1 NGS for Cancer Early Screening Segment by Type
1.2.2 NGS for Cancer Early Screening Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NGS FOR CANCER EARLY SCREENING MARKET OVERVIEW
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NGS FOR CANCER EARLY SCREENING MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global NGS for Cancer Early Screening Product Life Cycle
3.3 Global NGS for Cancer Early Screening Revenue Market Share by Company (2020-2025)
3.4 NGS for Cancer Early Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.5 Headquarters, Areas Served, and Product Types of Major Players
3.6 NGS for Cancer Early Screening Market Competitive Situation and Trends
3.6.1 NGS for Cancer Early Screening Market Concentration Rate
3.6.2 Global 5 and 10 Largest NGS for Cancer Early Screening Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NGS FOR CANCER EARLY SCREENING VALUE CHAIN ANALYSIS
4.1 NGS for Cancer Early Screening Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NGS FOR CANCER EARLY SCREENING MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global NGS for Cancer Early Screening Market Porter's Five Forces Analysis
6 NGS FOR CANCER EARLY SCREENING MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global NGS for Cancer Early Screening Market by Type (2020-2025)
6.3 Global NGS for Cancer Early Screening Market Size Growth Rate by Type (2021-2025)
7 NGS FOR CANCER EARLY SCREENING MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global NGS for Cancer Early Screening Market Size (M USD) by Application (2020-2025)
7.3 Global NGS for Cancer Early Screening Market Size Growth Rate by Application (2021-2025)
8 NGS FOR CANCER EARLY SCREENING MARKET SEGMENTATION BY REGION
8.1 Global NGS for Cancer Early Screening Market Size by Region
8.1.1 Global NGS for Cancer Early Screening Market Size by Region
8.1.2 Global NGS for Cancer Early Screening Market Size Market Share by Region
8.2 North America
8.2.1 North America NGS for Cancer Early Screening Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe NGS for Cancer Early Screening Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Spain
8.4 Asia Pacific
8.4.1 Asia Pacific NGS for Cancer Early Screening Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America NGS for Cancer Early Screening Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa NGS for Cancer Early Screening Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Guardant Health
9.1.1 Guardant Health Basic Information
9.1.2 Guardant Health NGS for Cancer Early Screening Product Overview
9.1.3 Guardant Health NGS for Cancer Early Screening Product Market Performance
9.1.4 Guardant Health SWOT Analysis
9.1.5 Guardant Health Business Overview
9.1.6 Guardant Health Recent Developments
9.2 Exact Sciences
9.2.1 Exact Sciences Basic Information
9.2.2 Exact Sciences NGS for Cancer Early Screening Product Overview
9.2.3 Exact Sciences NGS for Cancer Early Screening Product Market Performance
9.2.4 Exact Sciences SWOT Analysis
9.2.5 Exact Sciences Business Overview
9.2.6 Exact Sciences Recent Developments
9.3 Freenome
9.3.1 Freenome Basic Information
9.3.2 Freenome NGS for Cancer Early Screening Product Overview
9.3.3 Freenome NGS for Cancer Early Screening Product Market Performance
9.3.4 Freenome SWOT Analysis
9.3.5 Freenome Business Overview
9.3.6 Freenome Recent Developments
9.4 Epiginomics AG
9.4.1 Epiginomics AG Basic Information
9.4.2 Epiginomics AG NGS for Cancer Early Screening Product Overview
9.4.3 Epiginomics AG NGS for Cancer Early Screening Product Market Performance
9.4.4 Epiginomics AG Business Overview
9.4.5 Epiginomics AG Recent Developments
9.5 Bio-techne
9.5.1 Bio-techne Basic Information
9.5.2 Bio-techne NGS for Cancer Early Screening Product Overview
9.5.3 Bio-techne NGS for Cancer Early Screening Product Market Performance
9.5.4 Bio-techne Business Overview
9.5.5 Bio-techne Recent Developments
9.6 ThriveEarlier Detection
9.6.1 ThriveEarlier Detection Basic Information
9.6.2 ThriveEarlier Detection NGS for Cancer Early Screening Product Overview
9.6.3 ThriveEarlier Detection NGS for Cancer Early Screening Product Market Performance
9.6.4 ThriveEarlier Detection Business Overview
9.6.5 ThriveEarlier Detection Recent Developments
9.7 GRAIL, Inc.
9.7.1 GRAIL, Inc. Basic Information
9.7.2 GRAIL, Inc. NGS for Cancer Early Screening Product Overview
9.7.3 GRAIL, Inc. NGS for Cancer Early Screening Product Market Performance
9.7.4 GRAIL, Inc. Business Overview
9.7.5 GRAIL, Inc. Recent Developments
9.8 CellMax life
9.8.1 CellMax life Basic Information
9.8.2 CellMax life NGS for Cancer Early Screening Product Overview
9.8.3 CellMax life NGS for Cancer Early Screening Product Market Performance
9.8.4 CellMax life Business Overview
9.8.5 CellMax life Recent Developments
9.9 Berry Genomics
9.9.1 Berry Genomics Basic Information
9.9.2 Berry Genomics NGS for Cancer Early Screening Product Overview
9.9.3 Berry Genomics NGS for Cancer Early Screening Product Market Performance
9.9.4 Berry Genomics Business Overview
9.9.5 Berry Genomics Recent Developments
9.10 Singlera Genomics
9.10.1 Singlera Genomics Basic Information
9.10.2 Singlera Genomics NGS for Cancer Early Screening Product Overview
9.10.3 Singlera Genomics NGS for Cancer Early Screening Product Market Performance
9.10.4 Singlera Genomics Business Overview
9.10.5 Singlera Genomics Recent Developments
9.11 Geneseeq
9.11.1 Geneseeq Basic Information
9.11.2 Geneseeq NGS for Cancer Early Screening Product Overview
9.11.3 Geneseeq NGS for Cancer Early Screening Product Market Performance
9.11.4 Geneseeq Business Overview
9.11.5 Geneseeq Recent Developments
9.12 BGI Genomics
9.12.1 BGI Genomics Basic Information
9.12.2 BGI Genomics NGS for Cancer Early Screening Product Overview
9.12.3 BGI Genomics NGS for Cancer Early Screening Product Market Performance
9.12.4 BGI Genomics Business Overview
9.12.5 BGI Genomics Recent Developments
9.13 Burning Rock Biotech Limited
9.13.1 Burning Rock Biotech Limited Basic Information
9.13.2 Burning Rock Biotech Limited NGS for Cancer Early Screening Product Overview
9.13.3 Burning Rock Biotech Limited NGS for Cancer Early Screening Product Market Performance
9.13.4 Burning Rock Biotech Limited Business Overview
9.13.5 Burning Rock Biotech Limited Recent Developments
9.14 New Horizon Health Limited
9.14.1 New Horizon Health Limited Basic Information
9.14.2 New Horizon Health Limited NGS for Cancer Early Screening Product Overview
9.14.3 New Horizon Health Limited NGS for Cancer Early Screening Product Market Performance
9.14.4 New Horizon Health Limited Business Overview
9.14.5 New Horizon Health Limited Recent Developments
9.15 Yeasen Bio
9.15.1 Yeasen Bio Basic Information
9.15.2 Yeasen Bio NGS for Cancer Early Screening Product Overview
9.15.3 Yeasen Bio NGS for Cancer Early Screening Product Market Performance
9.15.4 Yeasen Bio Business Overview
9.15.5 Yeasen Bio Recent Developments
9.16 Hangzhou Aoru Biotech
9.16.1 Hangzhou Aoru Biotech Basic Information
9.16.2 Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Overview
9.16.3 Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Market Performance
9.16.4 Hangzhou Aoru Biotech Business Overview
9.16.5 Hangzhou Aoru Biotech Recent Developments
9.17 Amoy Diagnostics Co., Ltd.
9.17.1 Amoy Diagnostics Co., Ltd. Basic Information
9.17.2 Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Overview
9.17.3 Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Market Performance
9.17.4 Amoy Diagnostics Co., Ltd. Business Overview
9.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
9.18 Genetron Health
9.18.1 Genetron Health Basic Information
9.18.2 Genetron Health NGS for Cancer Early Screening Product Overview
9.18.3 Genetron Health NGS for Cancer Early Screening Product Market Performance
9.18.4 Genetron Health Business Overview
9.18.5 Genetron Health Recent Developments
9.19 AnchorDx
9.19.1 AnchorDx Basic Information
9.19.2 AnchorDx NGS for Cancer Early Screening Product Overview
9.19.3 AnchorDx NGS for Cancer Early Screening Product Market Performance
9.19.4 AnchorDx Business Overview
9.19.5 AnchorDx Recent Developments
10 NGS FOR CANCER EARLY SCREENING MARKET FORECAST BY REGION
10.1 Global NGS for Cancer Early Screening Market Size Forecast
10.2 Global NGS for Cancer Early Screening Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe NGS for Cancer Early Screening Market Size Forecast by Country
10.2.3 Asia Pacific NGS for Cancer Early Screening Market Size Forecast by Region
10.2.4 South America NGS for Cancer Early Screening Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Sales of NGS for Cancer Early Screening by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
11.1 Global NGS for Cancer Early Screening Market Forecast by Type (2026-2035)
11.1.1 Global NGS for Cancer Early Screening Market Size Forecast by Type (2026-2035)
11.2 Global NGS for Cancer Early Screening Market Forecast by Application (2026-2035)
11.2.1 Global NGS for Cancer Early Screening Market Size (M USD) Forecast by Application (2026-2035)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global NGS for Cancer Early Screening Market Size by Type (M USD)
Table 4. Global NGS for Cancer Early Screening Market Size by Application
Table 5. NGS for Cancer Early Screening Market Size Comparison by Region (M USD)
Table 6. Global NGS for Cancer Early Screening Revenue (M USD) by Company (2020-2025)
Table 7. Global NGS for Cancer Early Screening Revenue Share by Company (2020-2025)
Table 8. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NGS for Cancer Early Screening as of 2025)
Table 9. Headquarters, Areas Served, and Product Types of Major Players
Table 10. Product Type of Major Players
Table 11. Global NGS for Cancer Early Screening Company Market Concentration Ratio (CR5 and HHI)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. NGS for Cancer Early Screening Market Challenges
Table 18. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 19. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 20. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 21. Global NGS for Cancer Early Screening Market Size by Type (M USD)
Table 22. Global NGS for Cancer Early Screening Market Size (M USD) by Type (2020-2025)
Table 23. Global NGS for Cancer Early Screening Market Share by Type (2020-2025)
Table 24. Global NGS for Cancer Early Screening Market Size Growth Rate by Type (2021-2025)
Table 25. Global NGS for Cancer Early Screening Market Size by Application
Table 26. Global NGS for Cancer Early Screening Market Size by Application (2020-2025) & (M USD)
Table 27. Global NGS for Cancer Early Screening Market Share by Application (2020-2025)
Table 28. Global NGS for Cancer Early Screening Market Size Growth Rate by Application (2021-2025)
Table 29. Global NGS for Cancer Early Screening Market Size by Region (2020-2025) & (M USD)
Table 30. Global NGS for Cancer Early Screening Market Size Market Share by Region (2020-2025)
Table 31. North America NGS for Cancer Early Screening Market Size by Country (2020-2025) & (M USD)
Table 32. Europe NGS for Cancer Early Screening Market Size by Country (2020-2025) & (M USD)
Table 33. Asia Pacific NGS for Cancer Early Screening Market Size by Region (2020-2025) & (M USD)
Table 34. South America NGS for Cancer Early Screening Market Size by Country (2020-2025) & (M USD)
Table 35. Middle East and Africa NGS for Cancer Early Screening Market Size by Region (2020-2025) & (M USD)
Table 36. Guardant Health Basic Information
Table 37. Guardant Health NGS for Cancer Early Screening Product Overview
Table 38. Guardant Health NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 39. Guardant Health SWOT Analysis
Table 40. Guardant Health Business Overview
Table 41. Guardant Health Recent Developments
Table 42. Exact Sciences Basic Information
Table 43. Exact Sciences NGS for Cancer Early Screening Product Overview
Table 44. Exact Sciences NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 45. Exact Sciences SWOT Analysis
Table 46. Exact Sciences Business Overview
Table 47. Exact Sciences Recent Developments
Table 48. Freenome Basic Information
Table 49. Freenome NGS for Cancer Early Screening Product Overview
Table 50. Freenome NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 51. Freenome SWOT Analysis
Table 52. Freenome Business Overview
Table 53. Freenome Recent Developments
Table 54. Epiginomics AG Basic Information
Table 55. Epiginomics AG NGS for Cancer Early Screening Product Overview
Table 56. Epiginomics AG NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 57. Epiginomics AG Business Overview
Table 58. Epiginomics AG Recent Developments
Table 59. Bio-techne Basic Information
Table 60. Bio-techne NGS for Cancer Early Screening Product Overview
Table 61. Bio-techne NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 62. Bio-techne Business Overview
Table 63. Bio-techne Recent Developments
Table 64. ThriveEarlier Detection Basic Information
Table 65. ThriveEarlier Detection NGS for Cancer Early Screening Product Overview
Table 66. ThriveEarlier Detection NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 67. ThriveEarlier Detection Business Overview
Table 68. ThriveEarlier Detection Recent Developments
Table 69. GRAIL, Inc. Basic Information
Table 70. GRAIL, Inc. NGS for Cancer Early Screening Product Overview
Table 71. GRAIL, Inc. NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 72. GRAIL, Inc. Business Overview
Table 73. GRAIL, Inc. Recent Developments
Table 74. CellMax life Basic Information
Table 75. CellMax life NGS for Cancer Early Screening Product Overview
Table 76. CellMax life NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 77. CellMax life Business Overview
Table 78. CellMax life Recent Developments
Table 79. Berry Genomics Basic Information
Table 80. Berry Genomics NGS for Cancer Early Screening Product Overview
Table 81. Berry Genomics NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 82. Berry Genomics Business Overview
Table 83. Berry Genomics Recent Developments
Table 84. Singlera Genomics Basic Information
Table 85. Singlera Genomics NGS for Cancer Early Screening Product Overview
Table 86. Singlera Genomics NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 87. Singlera Genomics Business Overview
Table 88. Singlera Genomics Recent Developments
Table 89. Geneseeq Basic Information
Table 90. Geneseeq NGS for Cancer Early Screening Product Overview
Table 91. Geneseeq NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 92. Geneseeq Business Overview
Table 93. Geneseeq Recent Developments
Table 94. BGI Genomics Basic Information
Table 95. BGI Genomics NGS for Cancer Early Screening Product Overview
Table 96. BGI Genomics NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 97. BGI Genomics Business Overview
Table 98. BGI Genomics Recent Developments
Table 99. Burning Rock Biotech Limited Basic Information
Table 100. Burning Rock Biotech Limited NGS for Cancer Early Screening Product Overview
Table 101. Burning Rock Biotech Limited NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 102. Burning Rock Biotech Limited Business Overview
Table 103. Burning Rock Biotech Limited Recent Developments
Table 104. New Horizon Health Limited Basic Information
Table 105. New Horizon Health Limited NGS for Cancer Early Screening Product Overview
Table 106. New Horizon Health Limited NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 107. New Horizon Health Limited Business Overview
Table 108. New Horizon Health Limited Recent Developments
Table 109. Yeasen Bio Basic Information
Table 110. Yeasen Bio NGS for Cancer Early Screening Product Overview
Table 111. Yeasen Bio NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 112. Yeasen Bio Business Overview
Table 113. Yeasen Bio Recent Developments
Table 114. Hangzhou Aoru Biotech Basic Information
Table 115. Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Overview
Table 116. Hangzhou Aoru Biotech NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 117. Hangzhou Aoru Biotech Business Overview
Table 118. Hangzhou Aoru Biotech Recent Developments
Table 119. Amoy Diagnostics Co., Ltd. Basic Information
Table 120. Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Overview
Table 121. Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 122. Amoy Diagnostics Co., Ltd. Business Overview
Table 123. Amoy Diagnostics Co., Ltd. Recent Developments
Table 124. Genetron Health Basic Information
Table 125. Genetron Health NGS for Cancer Early Screening Product Overview
Table 126. Genetron Health NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 127. Genetron Health Business Overview
Table 128. Genetron Health Recent Developments
Table 129. AnchorDx Basic Information
Table 130. AnchorDx NGS for Cancer Early Screening Product Overview
Table 131. AnchorDx NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 132. AnchorDx Business Overview
Table 133. AnchorDx Recent Developments
Table 134. Global NGS for Cancer Early Screening Market Size Forecast by Region (2026-2035) & (M USD)
Table 135. North America NGS for Cancer Early Screening Market Size Forecast by Country (2026-2035) & (M USD)
Table 136. Europe NGS for Cancer Early Screening Market Size Forecast by Country (2026-2035) & (M USD)
Table 137. Asia Pacific NGS for Cancer Early Screening Market Size Forecast by Region (2026-2035) & (M USD)
Table 138. South America NGS for Cancer Early Screening Market Size Forecast by Country (2026-2035) & (M USD)
Table 139. Middle East and Africa NGS for Cancer Early Screening Market Size Forecast by Country (2026-2035) & (M USD)
Table 140. Global NGS for Cancer Early Screening Market Size Forecast by Type (2026-2035) & (M USD)
Table 141. Global NGS for Cancer Early Screening Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global NGS for Cancer Early Screening Market Size by Type (M USD)
Table 4. Global NGS for Cancer Early Screening Market Size by Application
Table 5. NGS for Cancer Early Screening Market Size Comparison by Region (M USD)
Table 6. Global NGS for Cancer Early Screening Revenue (M USD) by Company (2020-2025)
Table 7. Global NGS for Cancer Early Screening Revenue Share by Company (2020-2025)
Table 8. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NGS for Cancer Early Screening as of 2025)
Table 9. Headquarters, Areas Served, and Product Types of Major Players
Table 10. Product Type of Major Players
Table 11. Global NGS for Cancer Early Screening Company Market Concentration Ratio (CR5 and HHI)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. NGS for Cancer Early Screening Market Challenges
Table 18. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 19. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 20. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 21. Global NGS for Cancer Early Screening Market Size by Type (M USD)
Table 22. Global NGS for Cancer Early Screening Market Size (M USD) by Type (2020-2025)
Table 23. Global NGS for Cancer Early Screening Market Share by Type (2020-2025)
Table 24. Global NGS for Cancer Early Screening Market Size Growth Rate by Type (2021-2025)
Table 25. Global NGS for Cancer Early Screening Market Size by Application
Table 26. Global NGS for Cancer Early Screening Market Size by Application (2020-2025) & (M USD)
Table 27. Global NGS for Cancer Early Screening Market Share by Application (2020-2025)
Table 28. Global NGS for Cancer Early Screening Market Size Growth Rate by Application (2021-2025)
Table 29. Global NGS for Cancer Early Screening Market Size by Region (2020-2025) & (M USD)
Table 30. Global NGS for Cancer Early Screening Market Size Market Share by Region (2020-2025)
Table 31. North America NGS for Cancer Early Screening Market Size by Country (2020-2025) & (M USD)
Table 32. Europe NGS for Cancer Early Screening Market Size by Country (2020-2025) & (M USD)
Table 33. Asia Pacific NGS for Cancer Early Screening Market Size by Region (2020-2025) & (M USD)
Table 34. South America NGS for Cancer Early Screening Market Size by Country (2020-2025) & (M USD)
Table 35. Middle East and Africa NGS for Cancer Early Screening Market Size by Region (2020-2025) & (M USD)
Table 36. Guardant Health Basic Information
Table 37. Guardant Health NGS for Cancer Early Screening Product Overview
Table 38. Guardant Health NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 39. Guardant Health SWOT Analysis
Table 40. Guardant Health Business Overview
Table 41. Guardant Health Recent Developments
Table 42. Exact Sciences Basic Information
Table 43. Exact Sciences NGS for Cancer Early Screening Product Overview
Table 44. Exact Sciences NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 45. Exact Sciences SWOT Analysis
Table 46. Exact Sciences Business Overview
Table 47. Exact Sciences Recent Developments
Table 48. Freenome Basic Information
Table 49. Freenome NGS for Cancer Early Screening Product Overview
Table 50. Freenome NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 51. Freenome SWOT Analysis
Table 52. Freenome Business Overview
Table 53. Freenome Recent Developments
Table 54. Epiginomics AG Basic Information
Table 55. Epiginomics AG NGS for Cancer Early Screening Product Overview
Table 56. Epiginomics AG NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 57. Epiginomics AG Business Overview
Table 58. Epiginomics AG Recent Developments
Table 59. Bio-techne Basic Information
Table 60. Bio-techne NGS for Cancer Early Screening Product Overview
Table 61. Bio-techne NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 62. Bio-techne Business Overview
Table 63. Bio-techne Recent Developments
Table 64. ThriveEarlier Detection Basic Information
Table 65. ThriveEarlier Detection NGS for Cancer Early Screening Product Overview
Table 66. ThriveEarlier Detection NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 67. ThriveEarlier Detection Business Overview
Table 68. ThriveEarlier Detection Recent Developments
Table 69. GRAIL, Inc. Basic Information
Table 70. GRAIL, Inc. NGS for Cancer Early Screening Product Overview
Table 71. GRAIL, Inc. NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 72. GRAIL, Inc. Business Overview
Table 73. GRAIL, Inc. Recent Developments
Table 74. CellMax life Basic Information
Table 75. CellMax life NGS for Cancer Early Screening Product Overview
Table 76. CellMax life NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 77. CellMax life Business Overview
Table 78. CellMax life Recent Developments
Table 79. Berry Genomics Basic Information
Table 80. Berry Genomics NGS for Cancer Early Screening Product Overview
Table 81. Berry Genomics NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 82. Berry Genomics Business Overview
Table 83. Berry Genomics Recent Developments
Table 84. Singlera Genomics Basic Information
Table 85. Singlera Genomics NGS for Cancer Early Screening Product Overview
Table 86. Singlera Genomics NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 87. Singlera Genomics Business Overview
Table 88. Singlera Genomics Recent Developments
Table 89. Geneseeq Basic Information
Table 90. Geneseeq NGS for Cancer Early Screening Product Overview
Table 91. Geneseeq NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 92. Geneseeq Business Overview
Table 93. Geneseeq Recent Developments
Table 94. BGI Genomics Basic Information
Table 95. BGI Genomics NGS for Cancer Early Screening Product Overview
Table 96. BGI Genomics NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 97. BGI Genomics Business Overview
Table 98. BGI Genomics Recent Developments
Table 99. Burning Rock Biotech Limited Basic Information
Table 100. Burning Rock Biotech Limited NGS for Cancer Early Screening Product Overview
Table 101. Burning Rock Biotech Limited NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 102. Burning Rock Biotech Limited Business Overview
Table 103. Burning Rock Biotech Limited Recent Developments
Table 104. New Horizon Health Limited Basic Information
Table 105. New Horizon Health Limited NGS for Cancer Early Screening Product Overview
Table 106. New Horizon Health Limited NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 107. New Horizon Health Limited Business Overview
Table 108. New Horizon Health Limited Recent Developments
Table 109. Yeasen Bio Basic Information
Table 110. Yeasen Bio NGS for Cancer Early Screening Product Overview
Table 111. Yeasen Bio NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 112. Yeasen Bio Business Overview
Table 113. Yeasen Bio Recent Developments
Table 114. Hangzhou Aoru Biotech Basic Information
Table 115. Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Overview
Table 116. Hangzhou Aoru Biotech NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 117. Hangzhou Aoru Biotech Business Overview
Table 118. Hangzhou Aoru Biotech Recent Developments
Table 119. Amoy Diagnostics Co., Ltd. Basic Information
Table 120. Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Overview
Table 121. Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 122. Amoy Diagnostics Co., Ltd. Business Overview
Table 123. Amoy Diagnostics Co., Ltd. Recent Developments
Table 124. Genetron Health Basic Information
Table 125. Genetron Health NGS for Cancer Early Screening Product Overview
Table 126. Genetron Health NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 127. Genetron Health Business Overview
Table 128. Genetron Health Recent Developments
Table 129. AnchorDx Basic Information
Table 130. AnchorDx NGS for Cancer Early Screening Product Overview
Table 131. AnchorDx NGS for Cancer Early Screening Revenue (M USD) and Gross Margin (2020-2025)
Table 132. AnchorDx Business Overview
Table 133. AnchorDx Recent Developments
Table 134. Global NGS for Cancer Early Screening Market Size Forecast by Region (2026-2035) & (M USD)
Table 135. North America NGS for Cancer Early Screening Market Size Forecast by Country (2026-2035) & (M USD)
Table 136. Europe NGS for Cancer Early Screening Market Size Forecast by Country (2026-2035) & (M USD)
Table 137. Asia Pacific NGS for Cancer Early Screening Market Size Forecast by Region (2026-2035) & (M USD)
Table 138. South America NGS for Cancer Early Screening Market Size Forecast by Country (2026-2035) & (M USD)
Table 139. Middle East and Africa NGS for Cancer Early Screening Market Size Forecast by Country (2026-2035) & (M USD)
Table 140. Global NGS for Cancer Early Screening Market Size Forecast by Type (2026-2035) & (M USD)
Table 141. Global NGS for Cancer Early Screening Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Industry Chain of NGS for Cancer Early Screening
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global NGS for Cancer Early Screening Market Size (M USD), 2025-2035
Figure 5. Global NGS for Cancer Early Screening Market Size (M USD) (2020-2035)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. NGS for Cancer Early Screening Market Size by Country (M USD)
Figure 10. Company Assessment Quadrant
Figure 11. Global NGS for Cancer Early Screening Product Life Cycle
Figure 12. Global NGS for Cancer Early Screening Revenue Share by Company in 2025
Figure 13. NGS for Cancer Early Screening Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 14. The Global 5 and 10 Largest Players: Market Share by NGS for Cancer Early Screening Revenue in 2025
Figure 15. Value Chain Map of NGS for Cancer Early Screening
Figure 16. Global NGS for Cancer Early Screening Market PEST Analysis
Figure 17. Global NGS for Cancer Early Screening Market Porter's Five Forces Analysis
Figure 18. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 19. Global NGS for Cancer Early Screening Market Share by Type
Figure 20. Market Share of NGS for Cancer Early Screening by Type (2020-2025)
Figure 21. Global NGS for Cancer Early Screening Market Size Growth Rate by Type (2021-2025)
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global NGS for Cancer Early Screening Market Share by Application
Figure 24. Global NGS for Cancer Early Screening Market Share by Application (2020-2025)
Figure 25. Global NGS for Cancer Early Screening Market Share by Application in 2024
Figure 26. Global NGS for Cancer Early Screening Market Size Growth Rate by Application (2021-2025)
Figure 27. Global NGS for Cancer Early Screening Market Size Market Share by Region (2020-2025)
Figure 28. North America NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 29. North America NGS for Cancer Early Screening Market Size Market Share by Country in 2024
Figure 30. U.S. NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 31. Canada NGS for Cancer Early Screening Market Size (M USD) and Growth Rate (2020-2025)
Figure 32. Mexico NGS for Cancer Early Screening Market Size (M USD) and Growth Rate (2020-2025)
Figure 33. Europe NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 34. Europe NGS for Cancer Early Screening Market Share by Country in 2024
Figure 35. Germany NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 36. France NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 37. U.K. NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 38. Italy NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 39. Spain NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 40. Asia Pacific NGS for Cancer Early Screening Market Size and Growth Rate (M USD)
Figure 41. Asia Pacific NGS for Cancer Early Screening Market Size Market Share by Region in 2024
Figure 42. China NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 43. Japan NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. South Korea NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 45. India NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 46. Southeast Asia NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. South America NGS for Cancer Early Screening Market Size and Growth Rate (M USD)
Figure 48. South America NGS for Cancer Early Screening Market Size Market Share by Country in 2024
Figure 49. Brazil NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 50. Argentina NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Columbia NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 52. Middle East and Africa NGS for Cancer Early Screening Market Size and Growth Rate (M USD)
Figure 53. Middle East and Africa NGS for Cancer Early Screening Market Size Market Share by Region in 2024
Figure 54. Saudi Arabia NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 55. UAE NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 56. Egypt NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. Nigeria NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 58. South Africa NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. Global NGS for Cancer Early Screening Market Size Forecast by Value (2020-2035) & (M USD)
Figure 60. Global NGS for Cancer Early Screening Market Share Forecast by Type (2026-2035)
Figure 61. Global NGS for Cancer Early Screening Market Share Forecast by Application (2026-2035)
Figure 1. Industry Chain of NGS for Cancer Early Screening
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global NGS for Cancer Early Screening Market Size (M USD), 2025-2035
Figure 5. Global NGS for Cancer Early Screening Market Size (M USD) (2020-2035)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. NGS for Cancer Early Screening Market Size by Country (M USD)
Figure 10. Company Assessment Quadrant
Figure 11. Global NGS for Cancer Early Screening Product Life Cycle
Figure 12. Global NGS for Cancer Early Screening Revenue Share by Company in 2025
Figure 13. NGS for Cancer Early Screening Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 14. The Global 5 and 10 Largest Players: Market Share by NGS for Cancer Early Screening Revenue in 2025
Figure 15. Value Chain Map of NGS for Cancer Early Screening
Figure 16. Global NGS for Cancer Early Screening Market PEST Analysis
Figure 17. Global NGS for Cancer Early Screening Market Porter's Five Forces Analysis
Figure 18. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 19. Global NGS for Cancer Early Screening Market Share by Type
Figure 20. Market Share of NGS for Cancer Early Screening by Type (2020-2025)
Figure 21. Global NGS for Cancer Early Screening Market Size Growth Rate by Type (2021-2025)
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global NGS for Cancer Early Screening Market Share by Application
Figure 24. Global NGS for Cancer Early Screening Market Share by Application (2020-2025)
Figure 25. Global NGS for Cancer Early Screening Market Share by Application in 2024
Figure 26. Global NGS for Cancer Early Screening Market Size Growth Rate by Application (2021-2025)
Figure 27. Global NGS for Cancer Early Screening Market Size Market Share by Region (2020-2025)
Figure 28. North America NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 29. North America NGS for Cancer Early Screening Market Size Market Share by Country in 2024
Figure 30. U.S. NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 31. Canada NGS for Cancer Early Screening Market Size (M USD) and Growth Rate (2020-2025)
Figure 32. Mexico NGS for Cancer Early Screening Market Size (M USD) and Growth Rate (2020-2025)
Figure 33. Europe NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 34. Europe NGS for Cancer Early Screening Market Share by Country in 2024
Figure 35. Germany NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 36. France NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 37. U.K. NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 38. Italy NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 39. Spain NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 40. Asia Pacific NGS for Cancer Early Screening Market Size and Growth Rate (M USD)
Figure 41. Asia Pacific NGS for Cancer Early Screening Market Size Market Share by Region in 2024
Figure 42. China NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 43. Japan NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. South Korea NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 45. India NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 46. Southeast Asia NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. South America NGS for Cancer Early Screening Market Size and Growth Rate (M USD)
Figure 48. South America NGS for Cancer Early Screening Market Size Market Share by Country in 2024
Figure 49. Brazil NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 50. Argentina NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Columbia NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 52. Middle East and Africa NGS for Cancer Early Screening Market Size and Growth Rate (M USD)
Figure 53. Middle East and Africa NGS for Cancer Early Screening Market Size Market Share by Region in 2024
Figure 54. Saudi Arabia NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 55. UAE NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 56. Egypt NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. Nigeria NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 58. South Africa NGS for Cancer Early Screening Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. Global NGS for Cancer Early Screening Market Size Forecast by Value (2020-2035) & (M USD)
Figure 60. Global NGS for Cancer Early Screening Market Share Forecast by Type (2026-2035)
Figure 61. Global NGS for Cancer Early Screening Market Share Forecast by Application (2026-2035)
